CG Oncology (CGON) News Today $34.59 +1.03 (+3.07%) (As of 12/6/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancerDecember 6 at 1:18 PM | reuters.comCG Oncology's (CGON) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $66.00 price target on shares of CG Oncology in a report on Friday.December 6 at 10:17 AM | marketbeat.comCG Oncology's (CGON) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $75.00 target price on shares of CG Oncology in a research report on Friday.December 6 at 8:22 AM | marketbeat.comSUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardDecember 6 at 8:00 AM | globenewswire.comPoint72 Asset Management L.P. Has $28.15 Million Holdings in CG Oncology, Inc. (NASDAQ:CGON)Point72 Asset Management L.P. boosted its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 575.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 746,063 shares of the company'sDecember 6 at 5:43 AM | marketbeat.comPolar Asset Management Partners Inc. Takes $973,000 Position in CG Oncology, Inc. (NASDAQ:CGON)Polar Asset Management Partners Inc. purchased a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 25,800 shares of the company's stock, valued at approximately $973,000. SeveralDecember 6 at 5:43 AM | marketbeat.comJanus Henderson Group PLC Boosts Stake in CG Oncology, Inc. (NASDAQ:CGON)Janus Henderson Group PLC raised its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 7.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,526,534 shares of the company's stock after buying an aDecember 6 at 5:09 AM | marketbeat.comCG Oncology, Inc.: A Strong Buy on Promising NMIBC Treatment CretostimogeneDecember 6 at 4:43 AM | markets.businessinsider.comBuy Rating Recommended for CG Oncology Due to Promising Phase 3 Trial Results of CretostimogeneDecember 6 at 4:43 AM | markets.businessinsider.comCG Oncology Reports Promising Phase 3 Trial ResultsDecember 5 at 8:31 AM | tipranks.comGroundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerDecember 5 at 7:00 AM | globenewswire.comCG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Buy" by AnalystsCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has received a consensus rating of "Buy" from the nine research firms that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The averagDecember 5 at 2:06 AM | marketbeat.comFinancial Review: Artiva Biotherapeutics (NASDAQ:ARTV) & CG Oncology (NASDAQ:CGON)December 4 at 2:51 AM | americanbankingnews.comHighVista Strategies LLC Invests $594,000 in CG Oncology, Inc. (NASDAQ:CGON)HighVista Strategies LLC acquired a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,734 shares of the company's stock, valued at approximately $594,000December 3 at 7:10 AM | marketbeat.comArrowMark Colorado Holdings LLC Purchases 34,131 Shares of CG Oncology, Inc. (NASDAQ:CGON)ArrowMark Colorado Holdings LLC lifted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 17.4% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 230,390 shares of the company's stock after acquiring an additional 34,131 shares durinDecember 3 at 6:15 AM | marketbeat.comBraidwell LP Sells 138,632 Shares of CG Oncology, Inc. (NASDAQ:CGON)Braidwell LP cut its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 4.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,170,875 shares of the company's stock after selling 138,632 shares during the period. CG Oncology accounts forNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Acquires 88,390 Shares of CG Oncology, Inc. (NASDAQ:CGON)Ally Bridge Group NY LLC lifted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 50.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 263,266 shares of the company's stock after purchasing an additional 88,390 shares during the quarter. CG ONovember 28, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Stock Position Lessened by Yu FanYu Fan decreased its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 89.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 163,456 shares of the company's stock after selling 1,414,888 shares durNovember 28, 2024 | marketbeat.comABG WTT Global Life Science Capital Partners GP Ltd Sells 419,975 Shares of CG Oncology, Inc. (NASDAQ:CGON)ABG WTT Global Life Science Capital Partners GP Ltd lowered its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 45.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 495,526 shares of the company's stocNovember 28, 2024 | marketbeat.comCG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual MeetingNovember 20, 2024 | markets.businessinsider.comShort Interest in CG Oncology, Inc. (NASDAQ:CGON) Drops By 6.0%CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 5,600,000 shares, a decrease of 6.0% from the October 15th total of 5,960,000 shares. Currently, 13.9% of the company's shares are short sold. Based on an average daily volume of 638,000 shares, the short-interest ratio is currently 8.8 days.November 18, 2024 | marketbeat.comCG Oncology FY2024 EPS Estimate Lifted by Cantor FitzgeraldCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of CG Oncology in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company wilNovember 18, 2024 | marketbeat.comLos Angeles Capital Management LLC Takes Position in CG Oncology, Inc. (NASDAQ:CGON)Los Angeles Capital Management LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,052 shares oNovember 16, 2024 | marketbeat.comFY2024 EPS Estimates for CG Oncology Lifted by HC WainwrightCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for CG Oncology in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($1.33) per sharNovember 15, 2024 | marketbeat.comCG Oncology FY2024 EPS Forecast Increased by Lifesci CapitalCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Research analysts at Lifesci Capital upped their FY2024 earnings estimates for CG Oncology in a report issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($1.41) per share for theNovember 15, 2024 | marketbeat.comCG Oncology’s Financial Results and Clinical DevelopmentsNovember 14, 2024 | tipranks.comCG Oncology (NASDAQ:CGON) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPSCG Oncology (NASDAQ:CGON - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million.November 13, 2024 | marketbeat.comPromising Prospects for CG Oncology, Inc.: Buy Rating Reinforced by Positive MIBC Treatment Outcomes and Market OpportunitiesNovember 12, 2024 | markets.businessinsider.comCG Oncology Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 12, 2024 | markets.businessinsider.comCG Oncology (NASDAQ:CGON) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a report on Tuesday.November 12, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Position Increased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC increased its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 27.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 437,069 shares of the company's stock after buying an additional 94,010 shares duriNovember 11, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Buy" from AnalystsShares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one haNovember 10, 2024 | marketbeat.comDiscover the 3 Best-Performing Biotech IPO Stocks of 2024 (CGON)Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.November 6, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in OctoberCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 5,960,000 shares, a drop of 14.5% from the September 30th total of 6,970,000 shares. Based on an average trading volume of 703,100 shares, the short-interest ratio is currently 8.5 days. Approximately 14.8% of the shares of the company are short sold.October 29, 2024 | marketbeat.comCG Oncology initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of CG Oncology (CGON) with Buy RecommendationOctober 25, 2024 | msn.comCG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on shares of CG Oncology in a research report on Thursday. They set a "buy" rating and a $60.00 target price on the stock.October 24, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Rating of "Buy" from AnalystsCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has been given a consensus recommendation of "Buy" by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the coOctober 16, 2024 | marketbeat.comSG Americas Securities LLC Invests $664,000 in CG Oncology, Inc. (NASDAQ:CGON)SG Americas Securities LLC acquired a new position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,595 shares of the company's stock, valued at approximaOctober 14, 2024 | marketbeat.comOptimistic Outlook for CG Oncology as Trial Cessation Boosts Cretostimogene ProspectsOctober 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market OpportunitiesOctober 8, 2024 | markets.businessinsider.comBank of America Reaffirms "Buy" Rating for CG Oncology (NASDAQ:CGON)Bank of America reaffirmed a "buy" rating and set a $65.00 price target on shares of CG Oncology in a research note on Tuesday.October 8, 2024 | marketbeat.comRenaissance Technologies LLC Purchases 29,000 Shares of CG Oncology, Inc. (NASDAQ:CGON)Renaissance Technologies LLC lifted its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 204.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,200 shares of the company's stock after pOctober 5, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock, Short Interest ReportOctober 4, 2024 | benzinga.com75,982 Shares in CG Oncology, Inc. (NASDAQ:CGON) Bought by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 75,982 shares of the company's stock, valued at approximately $2,399,000. MarOctober 4, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON)Point72 Asset Management L.P. lessened its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 40.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,410 shares of theOctober 3, 2024 | marketbeat.comWe Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business GrowthOctober 1, 2024 | finance.yahoo.comCG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLCPerceptive Advisors LLC lowered its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 43.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 733,695 shares of the company's stock after sellingSeptember 30, 2024 | marketbeat.comEnsign Peak Advisors Inc Takes $1.91 Million Position in CG Oncology, Inc. (NASDAQ:CGON)Ensign Peak Advisors Inc acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 60,565 shares of the company's stock, valued at approximately $1,912,000. EnsignSeptember 28, 2024 | marketbeat.comBuy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market ProspectsSeptember 27, 2024 | markets.businessinsider.com Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years. Take these 4 steps today to protect your retirement NOW CGON Media Mentions By Week CGON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGON News Sentiment▼0.950.73▲Average Medical News Sentiment CGON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGON Articles This Week▼173▲CGON Articles Average Week Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Intra-Cellular Therapies News Today Revolution Medicines News Today Ascendis Pharma A/S News Today Legend Biotech News Today Nuvalent News Today Elanco Animal Health News Today Lantheus News Today Blueprint Medicines News Today Cytokinetics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGON) was last updated on 12/6/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredMedia Is Mocking Elon, But Wait Until They See This DemoElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredUrgent warning about your moneyThe stock market is booming … And Bitcoin just hiked through the roof. But don't get fooled by the "good...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
